Tauranga-based biotech company HoneyLab has kicked off a $15 million capital raising hot on the heels of a breakthrough deal to license its products in the US, Canada and Israel.
Under the deal, NYSE-listed Taro Pharmaceuticals has licensed seven HoneyLab products including its patented kanuka
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).
